Breast cancers overexpressing ER, PR, and/or HER2 can be specifically targeted with hormonal therapies, while TN breast cancers currently have no targeted therapy available and are limited to general cytotoxic chemotherapies [20]. Here, PGR is linked to breast carcinoma.